These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26002761)

  • 1. Daytime symptoms of restless legs syndrome--clinical characteristics and rotigotine effectiveness.
    Takahashi M; Ikeda J; Tomida T; Hirata K; Hattori N; Inoue Y
    Sleep Med; 2015 Jul; 16(7):871-6. PubMed ID: 26002761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
    Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
    Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
    Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
    Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
    Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
    Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
    Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
    Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
    Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
    J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
    Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
    Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
    Sixel-Döring F; Trenkwalder C
    Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine transdermal patch: in restless legs syndrome.
    Baldwin CM; Keating GM
    CNS Drugs; 2008; 22(10):797-806. PubMed ID: 18788832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
    Sun Y; van Valkenhoef G; Morel T
    Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
    Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
    Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for the management of restless leg syndrome.
    Toro BE
    J Neurosci Nurs; 2014 Aug; 46(4):227-32. PubMed ID: 24992148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
    Esteve V; Carneiro J; Salazar G; Pou M; Tapia I; Fulquet M; Duarte V; Saurina A; Moreno F; Ramírez de Arellano M
    Nefrologia (Engl Ed); 2018; 38(1):79-86. PubMed ID: 29198453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine for restless legs syndrome.
    Davies S
    Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
    Ferini-Strambi L; Marelli S; Galbiati A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.